Evercore ISI raised the firm’s price target on Charles River (CRL) to $260 from $250 and keeps an Outperform rating on the shares. Charles River’s 4Q book-to-bill ratio of about 1.1 times exceeded expectations and indicates a positive shift in biopharma end markets, “supporting a promising outlook for 2026,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River to buy KF Cambodia for $510M, exercises option for Pathoquest
- Charles River Labs Announces CEO Succession and Leadership Changes
- Charles River price target raised to $224 from $199 at Baird
- Charles River price target raised to $215 from $200 at Mizuho
- Orderly Leadership Transition and Governance Enhancements Support Continued Buy Rating on Charles River Labs